Study of the immune status in the treatment of calves with respiratory syndrome with the antiviral drug “Triazavirin”

¹ Federal State Budgetary Educational Institution of Higher Education “National research Mordovian state University N. P. Ogareva”, Saransk, Russian Federation
² Federal State Budgetary Educational Institution of Higher Education “Saint Petersburg State University of Veterinary Medicine”, Saint Petersburg, Russian Federation
³ Federal State Budgetary Educational Institution of Higher Education “Udmurt State Agrarian University”, Izhevsk, Udmurt Republic, Russian Federation

^* Corresponding author: rechetnikova77@mail.ru

Abstract

The article discusses the use of various treatment regimens for calves with respiratory syndrome using antibacterial and antiviral drugs, including Triazavirin. During the experiment, a study of immunological blood parameters was carried out - phagocytic activity of leukocytes (PAL), phagocytic number (PN), phagocytic index (PI). In relation to the control, the phagocytic activity of leukocytes changed significantly in the first and second experimental groups; there was an increase in this indicator by 26.14% and 44.61%. In turn, the absorption capacity also actively increases, the phagocytic number increases by 58.33% and 72.92%, the phagocytic index is higher by 28.81% and 33.9% in groups, respectively. In a comparative analysis of experimental groups with different treatment regimens, it was noted that in the second group, when taking the antiviral drug “Triazavirin” and the antibacterial drug “Lexoflon”, the indicators of phagocytic activity of leukocytes, phagocytic number, phagocytic index were higher by 1.05%, by 7.69 %, by 4.69% respectively. When using various medications and treatment regimens, including triazavirin, we observe activation of protective components and increased immune activity. The maximum quantitative value in terms of phagocytic activity and absorption capacity of leukocytes was observed in the second experimental group, with the use of the antiviral drug “Triazavirin” and the antibacterial drug “Lexoflon”.